E-mail this page
About Tasigna®
Tasigna Mechanism of Action
Tasigna is a next generation Bcr-Abl inhibitor for Ph+ CML. Tasigna was specifically designed to be a highly selective inhibitor of Bcr-Abl, the key cause and driver of Ph+ CML, and its mutations.
This animation shows how Tasigna binds Bcr-Abl with greater selectivity than imatinib, in vitro, and remains tightly bound to Bcr-Abl, causing inhibition of kinase activity and death of leukemic cells.
- Prescribing Tasigna
- Tasigna Efficacy
- Tasigna Safety and Tolerability
- European Summary of Product Characteristics
- Tasigna Mechanism of Action
- How to Dose
